CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,020 enrolled
Drug / intervention
low titer whole blood +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04684719
NCT04684719Phase 3Completed
CompareCT.gov

Type O Whole Blood and Assessment of Age During Prehospital Resuscitation (TOWAR) Trial

Jason Sperry·interventional·Posted Dec 24, 2020·Updated Feb 12, 2026

In Brief

A Phase 3 clinical trial evaluating low titer whole blood and Standard Care for Hemorrhagic Shock and Traumatic Injury. Completed, enrolled 1,020 participants across 10 sites.

Detailed Summary

Open label, multi-center, pre-hospital randomized trial utilizing 10 level-1 trauma centers designed to determine the efficacy and safety of low titer whole blood resuscitation as compared to standard of care resuscitation in patients at risk of hemorrhagic shock and to appropriately characterize the hemostatic competency of whole blood relative to its age.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHemorrhagic Shock, Traumatic Injury
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedDec 24, 2020
Enrollment StartApr 19, 2022
Primary CompletionJul 28, 2025
Study CompletionAug 12, 2025
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 5.5 years ago

Interventions

low titer whole bloodbiological

low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site

Standard Carebiological

crystalloid infusion or blood component transfusion resuscitation